Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01414244

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome — AT005291  

Diarrhea-Predominant Irritable Bowel Syndrome Clinical Trial

Official title:
Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Clinical Trial Summary

New and effective treatments are needed for patients with post-infectious irritable bowel syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy and safety of glutamine, an abundant amino acid in the body and the principal fuel for enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with increased intestinal permeability following an enteric infection.

Clinical Trial Description

In a double-blind trial, eligible adults with post-infectious IBS with increased intestinal permeability were randomly assigned to receive either glutamine (5 g three times daily) or placebo for eight weeks. The primary end point was the proportion of patients who had a reduction of ≥50 on the Irritable Bowel Severity Scoring System (IBS-SS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01414244
Study type Interventional
Source Tulane University
Contact
Status Completed
Phase Phase 2
Start date November 2010
Completion date December 30, 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04095988 - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) N/A
Completed NCT01736423 - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome Phase 3
Completed NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients
Completed NCT03977155 - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT02163213 - Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D N/A
Terminated NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg Phase 3
Not yet recruiting NCT06346847 - Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS N/A
Not yet recruiting NCT05687435 - Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2/Phase 3
Completed NCT01870895 - A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) Phase 3
Recruiting NCT05593367 - Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
Completed NCT02538692 - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Phase 2/Phase 3
Completed NCT03099785 - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Phase 2
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Completed NCT01350570 - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Phase 2/Phase 3